Time to Address the Cardiac Metabolic "Triple Whammy". Ischemic Heart Failure in Diabetic Patients**Editorials published in the Journal of the American College of Cardiology reflect the views of the authors and do not necessarily represent the views of JACC or the American College of Cardiology.

Journal of the American College of Cardiology

Volumn 48, Issue 11, 2006, Pages 2232-2234

  Horowitz, John D ^a   Kennedy, Jennifer A ^a  

^a UNIVERSITY OF ADELAIDE   (Australia)

Author keywords

[No Author keywords available]

Indexed keywords

CARDIOMYOPATHY; COHORT ANALYSIS; CONGESTIVE HEART FAILURE; DIABETES MELLITUS; DISEASE ASSOCIATION; EDITORIAL; EVIDENCE BASED MEDICINE; HUMAN; ISCHEMIC HEART DISEASE; PREVALENCE; PRIORITY JOURNAL; TREATMENT OUTCOME;

CARDIAC OUTPUT, LOW; DIABETES MELLITUS, TYPE 2; GLUCOSE; GLUCOSE TRANSPORTER TYPE 4; HUMANS; MYOCARDIAL ISCHEMIA; MYOCARDIUM;

EID: 33845197204     PISSN: 07351097     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.jacc.2006.09.010     Document Type: Editorial

References (31)

1. The CONSENSUS Trial Study Group. Effet of enalapril on mortality in severe congestive heart failure. N Engl J Med 316 (1987) 1429-1435
2. The SOLVD Investigators. Effect of enalapril on survival in patients with reduced left ventricular ejection fraction and congestive heart failure. N Engl J Med 325: (1991) 293-302
3. Shindler D.M., Kostis J.B., Yusuf S., et al. Diabetes mellitus: a predictor of morbidity and mortality in the Studies of Left Ventricular Dysfunction (SOLVD) trials and registry. Am J Cardiol 77 (1996) 1017-1020
4. Follath F., Cleland J.G., Klein W., and Murphy R. Etiology and response to drug treatment in heart failure. J Am Coll Cardiol 32 (1998) 1167-1172
5. Dries D.L., Sweitzer N.K., Drazner M.H., Stevenson L.W., and Gersh B.J. Prognostic impact of diabetes mellitus in patients with heart failure according to the etiology of left ventricular systolic dysfunction. J Am Coll Cardiol 38 (2001) 421-428
6. Domanski M., Kraus-Steinrauf H., Deedwania P., et al. The effect of diabetes on outcomes of patients with advanced heart failure in the BEST trial. J Am Coll Cardiol 42 (2003) 914-922
7. Sanbe A., Tanonaka K., Hanaoka Y., Katoh T., and Takeo S. Regional energy metabolism of failing hearts following myocardial infarction. J Mol Cell Cardiol 25 (1993) 995-1013
8. 31P-SLOOP magnetic resonance spectroscopy. J Am Coll Cardiol 40 (2002) 1267-1274
9. Stanley W.C., Recchia F.A., and Lopaschuk G.D. Myocardial substrate metabolism in the normal and failing heart. Physiol Rev 85 (2005) 1093-1129
10. Taylor M., Wallhaus T.R., DeGrado T.R., et al. An evaluation of myocardial fatty acid and glucose uptake using PET with [18F]fluoro-6-thia-heptadecanoic acid and [18F]FDG in patients with congestive heart failure. J Nucl Med 42 (2001) 55-62
11. Paolisso G., Gambardella A., Galzerano D., et al. Total body and myocardial substrate oxidation in congestive heart failure. Metabolism 43 (1994) 174-179
12. Davila-Roman V.G., Vedala G., Herrero P., et al. Altered myocardial fatty acid and glucose metabolism in idiopathic dilated cardiomyopathy. J Am Coll Cardiol 40 (2002) 271-277
13. Sack M.N., Rader T.A., Park S., Bastin J., McCune S.A., and Kelly D.P. Fatty acid oxidation enzyme gene expression is downregulated in the failing heart. Circulation 94 (1996) 2837-2842
14. Chandler M.P., Kerner J., Huang H., et al. Moderate severity heart failure does not involve a downregulation of myocardial fatty acid oxidation. Am J Physiol Heart Circ Physiol 287 (2004) H1538-H1543
15. Recchia F.A., McConnell P.I., Bernstein R.D., Vogel T.R., Xu X., and Hintze T.H. Reduced nitric oxide production and altered myocardial metabolism during the decompensation of pacing-induced heart failure in the conscious dog. Circ Res 83 (1998) 969-979
16. Lei B., Lionetti V., Young M.E., et al. Paradoxical downregulation of the glucose oxidation pathway despite enhanced flux in severe heart failure. J Mol Cell Cardiol 36 (2004) 567-576
17. Razeghi P., Young M.E., Alcorn J.L., Moravec C.S., Frazier O.H., and Taegtmeyer H. Metabolic gene expression in fetal and failing human heart. Circulation 104 (2001) 2923-2931
18. Swan J.W., Anker S.D., Walton C., et al. Insulin resistance in chronic heart failure: relation to severity and etiology of heart failure. J Am Coll Cardiol 30 (1997) 527-532
19. Doehner W., Rauchhaus M., Ponikowski P., et al. Impaired insulin sensitivity as an independent risk factor for mortality in patients with stable chronic heart failure. J Am Coll Cardiol 46 (2005) 1019-1026
20. Witteles R.M., Tang W.H.W., Jamali A.H., Chu J.W., Reaven G.M., and Fowler M.B. Insulin resistance in idiopathic dilated cardiomyopathy. J Am Coll Cardiol 44 (2004) 78-81
21. Utriainen T., Takala T., Luotolahti M., et al. Insulin resistance characterises glucose uptake in skeletal muscle but not in the heart in NIDDM. Diabetologia 41 (1998) 555-559
22. Scheuermann-Freestone M., Madsen P.L., Manners D., et al. Abnormal cardiac and skeletal muscle energy metabolism in patients with type 2 diabetes. Circulation 107 (2003) 3040-3046
23. Dutka D.P., Pitt M., Pagoano D., et al. Myocardial glucose transport and utilization in patients with type 2 diabetes mellitus, left ventricular dysfunction, and coronary artery disease. J Am Coll Cardiol 48 (2006) 2225-2231
24. Murray A.J., Lygate C.A., Cole M.A., et al. Insulin resistance, abnormal energy metabolism and increased ischemic damage in the chronically infarcted rat heart. Cardiovasc Res 71 (2006) 149-157
25. Nikolaidis L.A., Sturzu A., Stolarski C., Elahi D., Shen Y.-T., and Shannon R.P. The development of myocardial insulin resistance in conscious dogs with advanced dilated cardiomyopathy. Cardiovasc Res 61 (2004) 297-306
26. Nesto R.W., Bell D., Bonow R.O., et al. Thiazolidinedione use, fluid retention, and congestive heart failure: a consensus statement from the American Heart Association and American Diabetes Association. Diabetes Care 27 (2004) 256-263
27. Kennedy J.A., Unger S.A., and Horowitz J.D. Inhibition of carnitine palmitoyltransferase-1 in rat heart and liver by perhexiline and amiodarone. Biochem Pharmacol 52 (1996) 273-280
28. Lee L., Campbell R., Scheuermann-Freestone M., et al. Metabolic modulation with perhexiline in chronic heart failure: a randomized controlled trial of short-term use of novel treatment. Circulation 112 (2005) 3280-3288
29. Kantor P.F., Lucien A., Kozak R., and Lopaschuk G.D. The antianginal drug trimetazidine shifts cardiac energy metabolism from fatty acid oxidation to glucose oxidation by inhibiting mitochondrial long-chain 3-ketoacyl coenzyme A thiolase. Circ Res 86 (2000) 580-588
30. Fragasso G., Piatti P.M., Monti L., et al. Short- and long-term beneficial effects of trimetazidine in patients with diabetes and ischemic cardiomyopathy. Am Heart J 146; (2003) e18
31. Fragasso G., Perseghin G., De Cobelli F., et al. Effects of metabolic modulation by trimetazidine on left ventricular function and phosphocreatine/adenosine triphosphate ratio in patients with heart failure. Eur Heart J 27 (2006) 942-948